In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's Bid for Revival

Executive Summary

Without the revenue increases to fuel R&D budget growth, Bristol-Myers' new CSO James Palmer must make more of existing assets. As he describes it in this interview, his conservative approach is symbolic of an entire industry waking up to its over-reliance on internal discovery and unvalidated targets. And as part of his risk-lowering strategy, he will continue to move the company away from low-acuity primary-care markets to far more specialized, higher-acuity segments where safety is less of a concern with regulators than efficacy.

You may also be interested in...



Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss

Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.

Generic Plavix: As Bristol Swoons, Broad Implications

The immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.

Generic Plavix: As Bristol Swoons, Broad Implications

The immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel